The Food and Drug Administration’s final guidance, “Circumstances that Constitute Delaying, Limiting, or Refusing a Drug Inspection,” describes manufacturer actions the agency views as “delaying, denying, or limiting inspection, or refusing to permit entry or inspection.”
FDA Explains Reasons For Delaying, Limiting Or Refusing Inspections In Final Guidance
The US FDA has issued its final guidance defining manufacturer behaviors it deems as hampering the agency’s ability to conduct an inspection. In a previous draft guidance, the agency expanded its longstanding policy on inspections of drug companies to include device makers as well.
More from Regulation
• By
Single-use packaging producers subject to Oregon state’s Extended Producer Responsibility law that didn’t meet the 31 March deadline to report their packaging materials are given a grace period to report until 30 April, says Circular Action Alliance, the organization carrying out the EPR program.
• By
Reclassifying ethanol as a carcinogenic, mutagenic, or reprotoxic substance - something the European Chemicals Agency seems likely to do in the near future - would be “tantamount to a de facto ban” with “fatal consequences” for medical care in Germany, says Pharma Deutschland in a joint paper with 13 other German healthcare industry associations.
• By
Personal care companies selling in California that suspect they are subject to its listing of a common stabilizer and packaging material should collect Certificates of Analysis for all raw materials, pursue third-party formula testing and retain counsel.
• By
Single-use packaging producers subject to California’s SB 54 recycling law, which implements a statewide EPR plan, should continue to prepare for its implementation, even as they enter a ‘prolonged period of uncertainty,’ says consultant Michael Washburn.
More from Policy & Regulation
• By
Data from the US Food and Drug Administration indicated that two hair dye ingredients are formulated in eye makeup and dermal application products, prompting a Cosmetic Ingredient Review panel to conclude one dye is unsafe for such uses and discouraging those uses in the other dye.
• By
Preliminary registration data released by FDA offers a first glimpse of the Modernization of Cosmetics Regulation Act’s impact on information the agency has at hand.
• By
Counterfeit beauty products cost the US industry an estimated $3bn in 2023, says a trade expert during the Personal Care Products Council’s Beauty Collective Summit.